Arrowhead Reports Q3 Earnings: $1.26 EPS, $27.76M Revenue

Arrowhead Pharmaceuticals reported Q3 EPS of $1.26, beating consensus of $1.10, and revenue of $27.76M, below consensus of $29.01M. The company's CEO said it has a mature pipeline with four candidates in Phase 3 studies and a strong balance sheet to fund new medicines.

Title: Arrowhead Pharmaceuticals Reports Q3 Earnings, CEO Highlights Mature Pipeline

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported its third-quarter (Q3) earnings for the fiscal year 2025, with earnings per share (EPS) of $1.26, beating the consensus estimate of $1.10. Revenue for the quarter came in at $27.76 million, falling short of the FactSet estimate of $29.01 million [1].

The company's President and CEO, Christopher Anzalone, Ph.D., highlighted the maturity of Arrowhead's pipeline, noting that four of its discovered candidates are currently in pivotal Phase 3 studies. He also emphasized the company's strong balance sheet, which provides the financial resources necessary to move multiple innovative new medicines through the clinical and regulatory process [2].

Arrowhead Pharmaceuticals has been actively expanding its pipeline and commercial buildout, with several key developments during the quarter. The company signed an asset purchase agreement with Sanofi for the development and commercialization of four investigational cardiometabolic candidates in Greater China. Additionally, Arrowhead earned a $100 million milestone payment from Sarepta Therapeutics for reaching the first of two prespecified enrollment targets in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for type 1 myotonic dystrophy (DM1). The company also completed enrollment in its global Phase 3 clinical studies for plozasiran, supporting regulatory submissions for marketing approval [2].

Despite the revenue shortfall, Arrowhead's financial position remains robust. As of June 30, 2025, the company reported total cash resources of $900.37 million, up from $680.96 million at the end of September 2024. The company's total assets stood at $1,380.61 million, with total liabilities of $860.80 million, providing a strong foundation for future growth and innovation [2].

Arrowhead Pharmaceuticals will host a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the quarterly results in more detail. Investors are encouraged to attend and participate in the webcast, available on the company's website [2].

References:
[1] https://www.marketscreener.com/news/earnings-flash-arwr-arrowhead-pharmaceuticals-inc-reports-q3-revenue-27-8m-vs-factset-est-of-ce7c5edcd988f725
[2] https://www.stocktitan.net/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2025-third-quarter-nat5ezohsodz.html